Febuxostat tablet

A technology of febuxostat and tablets, which is applied in the field of medicine, can solve the problems of febuxostat's medicinal effect not meeting the ideal requirements, high medicinal content of febuxostat, and low bioavailability, and achieve improved Effects of bioavailability, quality control, enhanced solubility and stability

CN102895209AActive Publication Date: 2013-01-30KANGYA OF NINGXIA PHARMA
3 Cites 10 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2013-01-30

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a Febuxostat tablet. The Febuxostat tablet comprises a tablet core and a coating, wherein the tablet core comprises the following components in weight percentage: 5-30 percent of Febuxostat, 15-60 percent of filler, 1-20 percent of disintegrating agent, 0.1-5 percent of surface active agent, 0.1-8 percent of lubricant and a right amount of adhesive. According to the Febuxostat tablet, trough adopting the powerful disintegrating agent within a reasonable proportional region, and meanwhile, through jointly using the surface active agent, the poorly water-soluble drug Febuxostat dissolves out, and further, the dissolvability of the Febuxostat is increased, and the bioavailability of the Febuxostat is improved. Moreover, the Febuxostat tablet is simple in preparation method, controllable in quality and high in stability.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of medicine, in particular to a febuxostat tablet. Background technique

[0002] The occurrence of gout is due to the excessive production of uric acid in the body and the decline in the ability of the kidneys to clear it. The accumulation of uric acid in the body leads to the deposition of urate crystals in the joints and various organs. Uric acid has no physiological function in the human body. Under normal circumstances, 2 / 3 of the uric acid produced in the body is excreted by the kidneys, and the remaining 1 / 3 is excreted from the intestines. Uric acid in the body is constantly produced and excreted, so it maintains a certain concentration in the blood. The uric acid contained in each liter of blood of normal people is less than 0.42mmol for men and no more than 0.357mmol for women. In the process of synthesis and decomposition of purine, various enzymes are involved. Due to the congenital abnormality of the enz...

Examples

Embodiment 1

[0031] Tablet prescription:

[0032]

[0033] Adhesive

[0034]

[0035] Coating Solution Prescription

[0036]

[0037] Preparation Process:

[0038] 1. Mix the prescribed amount of febuxostat, lactose and sodium lauryl sulfate evenly, and then pulverize it with an ultrafine pulverizer to control the average particle size below 50 μm;

[0039] 2. Mix the pulverized mixture with the prescribed amount of microcrystalline cellulose and 10 g of carboxymethyl starch sodium evenly, then add 8% of the binder to make soft material from starch slurry, and pass through a 18-mesh sieve to make wet granules;

[0040] 3. Put the wet granules in a drying oven, and dry them with blast at 50-60°C;

[0041] 4. Pass the dry granules through a 18-mesh sieve for granulation, add the prescribed amount of lubricant and the remaining sodium starch glycolate, mix well, and press into tablets to obtain tablet cores;

[0042] 5. Coating with Opadry ethanol solution, the weight gain of the c...

example 2

[0047] Tablet core prescription

[0048]

[0049] Adhesive:

[0050] Coating liquid prescription:

[0051]

[0052]

[0053] Preparation Process

[0054] 1. Mix the prescribed amount of febuxostat, pre-crossed starch and Tween evenly, and then pulverize it with an ultrafine pulverizer, and control the average particle size below 30 μm;

[0055] 2. After mixing the pulverized mixture with the prescription amount of microcrystalline cellulose and 10g sodium starch glycolate / , add adhesive 8% starch slurry to make a soft material, and pass through a 18-mesh sieve to make wet granules;

[0056] 3. Put the wet granules in a drying oven, and dry them with blast at 50-60°C;

[0057] 4. Pass the dry granules through a 18-mesh sieve for granulation, add the prescribed amount of lubricant and the remaining sodium starch glycolate, mix well, and press into tablets to obtain tablet cores;

[0058] 5. Coating with Opadry ethanol solution, the weight gain of the coating is ab...

example 3

[0062] Tablet prescription:

[0063]

[0064] adhesive

[0065]

[0066] Coating Solution Prescription

[0067]

[0068] craft

[0069] 1. Mix the prescribed amount of febuxostat, lactose and sodium lauryl sulfate evenly, and then pulverize it with an ultrafine pulverizer, and control the average particle size below 30 μm;

[0070] 2. Mix the pulverized mixture with the prescribed amount of microcrystalline cellulose and 10 g of carboxymethyl starch sodium evenly, then add 8% of the binder to make soft material from starch slurry, and pass through a 18-mesh sieve to make wet granules;

[0071] 3. Put the wet granules in a drying oven, and dry them with blast at 50-60°C;

[0072] 4. Pass the dry granules through a 18-mesh sieve for granulation, add the prescribed amount of lubricant and the remaining sodium starch glycolate, mix well, and press into tablets to obtain tablet cores;

[0073] 5. Coating with Opadry ethanol solution, the weight gain of the coating is a...